Abstract: The present invention is a pharmaceutical or food composition comprising a pretreated extract and an isolate and an isolated and purified product of Cinnamomum cassia showing a pharmacological effect. It relates to an active ingredient showing physiological activity in the Cinnamomum cassia extract.

Abstract: The present invention relates to donepezil ether palmitate hydrochloride (DEP HCl) and a method for preparing same. Donepezil ether palmitate hydrochloride (DEP HCl) has been developed to have increased stability by suppressing generation of unknown related substances generated during a preparation process of a raw material and formulation of donepezil ether palmitate (DEP). In addition, the present invention relates to a sustained-release pharmaceutical composition comprising donepezil ether palmitate hydrochloride (DEP HCl) as a main ingredient. When administered in the body, the initial release of donepezil, which is an active ingredient, is reduced, thereby reducing the risk of side effects such as drug toxicity, and the constant release of donepezil in the body for a long period of time can improve the drug treatment effect on dementia patients.

Abstract: The present invention relates to a stable pharmaceutical composition comprising omeprazole, its enantiomer, or its pharmaceutically acceptable salt, and sodium bicarbonate. Specifically, the present invention relates to a pharmaceutical composition with improved stability comprising a low dose of sodium bicarbonate, so that it has improved dissolution rate and bioavailability and also reduces side effects resulting from a high dose of sodium bicarbonate.

Abstract: The present invention relates to novel donepezil ether palmitate or a pharmaceutically acceptable salt thereof; and a sustained-release pharmaceutical composition containing same as a main ingredient. Since an ether palmitate group is introduced to donepezil, the donepezil ether palmitate of the present invention reduces the initial release of donepezil, which is the active ingredient, when administered into the body, so as to reduce the risk of side effects such as drug toxicity, and allows donepezil to be uniformly released in the body over a long time to increase drug treatment effects for dementia patients.

Abstract: The present invention relates to a stable pharmaceutical formulation comprising omeprazole, its enantiomer, or its pharmaceutically acceptable salt, and sodium bicarbonate, and a method for preparing the same. Specifically, the present invention provides a stable formulation by preventing omeprazole, its enantiomer, or its pharmaceutically acceptable salt, from coming in direct contact with sodium bicarbonate, to reduce the production of impurities.

Abstract: The present invention relates to a pharmaceutical preparation comprising omeprazole, an enantiomer thereof or a pharmaceutically acceptable salt thereof, and sodium bicarbonate, and a method for preparing the same. Specifically, the present invention relates to a pharmaceutical preparation, wherein a first mixed part comprising esomeprazole comprises 40% by weight or less of sodium bicarbonate based on the total weight of sodium bicarbonate comprised in the preparation, and thus sodium bicarbonate is first dissolved so as to raise pH, and then esomeprazole is dissolved such that the release properties of an active ingredient are improved, and thus the dissolution pattern and bioavailability of a drug can be enhanced.

Abstract: The present invention relates to a stable pharmaceutical composition comprising an omeprazole, an enantiomer thereof or a pharmaceutically acceptable salt thereof, and sodium bicarbonate. Specifically, the present invention relates to a pharmaceutical composition having improved stability, which includes a low content of sodium bicarbonate and has excellent dissolution rate and bioavailability and a reduced side effect due to a high content of sodium bicarbonate.

Abstract: The present invention relates to a pharmaceutical preparation comprising omeprazole, an enantiomer thereof or a pharmaceutically acceptable salt thereof, and sodium bicarbonate, and a method for preparing the same. Specifically, the present invention relates to a pharmaceutical preparation in which sodium bicarbonate is first disintegrated so as to raise pH, and then omeprazole is dissolved such that the release properties of an active ingredient are improved, and thus the dissolution pattern and bioavailability of a drug can be enhanced.

Abstract: The present invention relates to a stable pharmaceutical composition comprising omeprazole, its enantiomer, or its pharmaceutically acceptable salt, and sodium bicarbonate. Specifically, the present invention relates to a pharmaceutical composition with improved stability comprising a low dose of sodium bicarbonate, so that it has improved dissolution rate and bioavailability and also reduces side effects resulting from a high dose of sodium bicarbonate.

Abstract: The present invention relates to a stable pharmaceutical formulation comprising omeprazole, its enantiomer, or its pharmaceutically acceptable salt, and sodium bicarbonate, and a method for preparing the same. Specifically, the present invention provides a stable formulation by preventing omeprazole, its enantiomer, or its pharmaceutically acceptable salt, from coming in direct contact with sodium bicarbonate, to reduce the production of impurities.

Abstract: The present invention relates to a pharmaceutical composition with enhanced stability, containing pemetrexed or a salt thereof, and a preparation method therefor. The present invention provides an injection preparation in liquid form containing pemetrexed, capable of ensuring sufficient stability during circulation and storage by selection of an optimum material and setting of an optimum concentration range in order to secure the stability of pemetrexed. The present invention can provide a pemetrexed preparation which is readily commercially prepared, can prevent microbial contamination occurring during lyophilization or reconstitution, and has enhanced convenience of administration and stability.

Abstract: The present invention relates to a pharmaceutical composition with enhanced stability, containing pemetrexed or a salt thereof, and a preparation method therefor. The present invention provides an injection preparation in liquid form containing pemetrexed, capable of ensuring sufficient stability during circulation and storage by selection of an optimum material and setting of an optimum concentration range in order to secure the stability of pemetrexed. The present invention can provide a pemetrexed preparation which is readily commercially prepared, can prevent microbial contamination occurring during lyophilization or reconstitution, and has enhanced convenience of administration and stability.

Abstract: The present invention relates to a coated particle of amlodipine maleate and a pharmaceutical composition for cardiovascular disease (CVD) comprising the coated particle of amlodipine maleate. The pharmaceutical composition of the present invention has stable bioavailability due to sufficient dissolution rate and prevents decomposition reaction of amlodipine to thereby being formulated with formulation-stability equal to or higher than amlodipine besylate under long storage.